Chemotactic Anti-Tumour Antibodies: In Vitro Results with Four Different Antibody Preparations

  • R. Obrist
  • J. P. Obrecht
  • R. C. BastJr.
  • A. L. Sandberg


The biological behaviour and prognosis of a tumour may be related to the number of intratumour inflammatory cells. However, based on retrospective analysis, tumour infiltrating inflammatory cells have been associated with suppression of metastasis1, or, to the contrary, enhancement of tumour growth2. Recently, we demonstrated that prospective enhancement of tumour infiltrating macrophage numbers in vivo is possible by the administration of anti-tumour heteroantibodies covalently coupled to the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP)3. Using mouse monoclonal antibodies (moab), which have the advantages of being of one molecular species only and of virtually unlimited supply, a more strict evaluation of the biological role of tumour infiltrating macrophages might therefore become feasible. We already demonstrated in vitro chemotactic activity and antigen recognition function of moab-fMLP conjugates similar to the hetero-antibody-fMLP conjugate4,5. Whereas a similar average number of binding sites can be assumed for different polyclonal antibodies, conjugation of fMLP to moab is limited by the available number of binding sites on the given moab molecule, which might differ from one moab species to another. In this paper, the in vitro chemotactic activity of polyclonal IgM and IgG conjugates and of three different moab-conjugates is compared.


Migration Alanine Peri Carbodiimide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S.A. Eccles, and P. Alexander, Macrophage Content of Tumours in Relation to Metastatic Spread and Host Immune Reaction, Nature 250: 667 (1974).PubMedCrossRefGoogle Scholar
  2. 2.
    R.T. Prehn, Immunostimulation of the Lymphodependent Phase of Neoplastic Growth, J. Natl. Cancer Inst. 59: 1043 (1977).PubMedGoogle Scholar
  3. 3.
    R. Obrist, and A.L. Sandberg, Enhancement of Macrophage Invasion of Tumors by Administration of Chemotactic Factor - Antitumor Antibody Conjugates, Cellular Immunology 81: 169 (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    R. Obrist, and A.L. Sandberg, In Vitro Effects of Antitumor Antibody - Chemotactic Factor Complexes, Clin. Immunol. Immunopathol. 25: 91 (1982).PubMedCrossRefGoogle Scholar
  5. 5.
    R. Obrist, R. Reilly, T. Leavitt, R.C. Knapp, and R.C. Bast, Jr., Monocyte Chemotaxis Mediated by Formyl-Methionyl-Leucyl-Phenyl- alanine Conjugated with Monoclonal Antibodies Against Human Ovarian Carcinoma, Int. J. Immunopharmac. 5: 307 (1983).CrossRefGoogle Scholar
  6. 6.
    R.C. Bast, M. Feeney, M. Lazarus, L.M. Nadler, R.B. Colvin, and R.C. Knapp, Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma, J. Clin. Invest. 68: 1331 (1981).PubMedCrossRefGoogle Scholar
  7. 7.
    J.P. Brown, K. Nishiyama, I. Hellstroem, K.E. Hellstroem, Structural Characterization of Human Melanoma - Associated Antigen p97 Using Monoclonal Antibodies, J. Immunol. 127: 539 (1981).PubMedGoogle Scholar
  8. 8.
    R. Obrist, Monoclonal Antibodies as Drug Carriers in Oncology, Trends in Pharmacological Sciences 4: 375 (1983).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • R. Obrist
    • 1
  • J. P. Obrecht
    • 1
  • R. C. BastJr.
    • 2
  • A. L. Sandberg
    • 3
  1. 1.Div. of OncologyDept. of Internal Medicine of the University, KantonsspitalBaselsSwitzerland
  2. 2.Dana Farber Cancer CenterBostonUSA
  3. 3.Lab. of Microbiology and ImmunologyNIDR, NIH BethesdaUSA

Personalised recommendations